Bristol-Myers Squibb Taps Cravath for ImClone Deal

August 1, 2008 Cravath, Swaine & Moore is advising Bristol-Myers Squibb on the planned acquisition of the rest of ImClone Systems, the maker of the best-selling cancer drug Erbitux, for $4.5 billion.

Corporate partner Allen Finkelson is leading the Cravath team, which includes corporate partners Thomas Dunn and Susan Webster, and tax partners Stephen Gordon and Lauren Angelilli.


comments powered by Disqus